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Abstract
The coordinated iron structure and ferrochelatase binding surface of human frataxin have been
characterized to provide insight into the protein’s ability to serve as the iron chaperone during heme
biosynthesis.
Frataxin, a mitochondrial protein essential for cellular iron homeostasis, was recently
implicated as the iron chaperone that delivers Fe(II) to enzyme partners during cellular heme
and Fe–S cluster biosynthesis. Frataxin deficiency in humans is the cause of the
neurodegenerative disorder Friedreich’s ataxia (FRDA) affecting 1 in 50,000.1 The
trinucleotide repeat expansion in the first intron of the frataxin gene disrupts transcription,
causing a frataxin deficiency that results in disruption of cellular iron homeostasis, progressive
mitochondrial iron accumulation and a deficiency in heme and Fe–S clusters; the effects of
these lead to a loss of cell viability and eventually patient death.1,2 The iron binding ability of
frataxin has been well documented,3–5 with monomeric protein binding multiple iron atoms
at micromolar binding affinities.6–9 Frataxin binds at nanomolar affinity to the ferrochelatase
and the iron–sulfur cluster (ISU) assembly apparatus, enzymes responsible for heme and Fe–
S cluster bioassembly respectively.6,7,10 Frataxin utilizes surface exposed helical plane
residues to establish a binding interface with ferrochelatase.5 Furthermore, the presence of
frataxin stimulates in vitro assembly of both heme and Fe–S clusters.6,7,11 Combined, these
results suggest frataxin plays a direct role in Fe(II) delivery within the two separate Fe-cofactor
production pathways.
Regarding the heme biosynthetic pathway, we have performed a detailed characterization of
frataxin bound iron and the protein’s ferrochelatase binding structure to provide additional
insight into how frataxin delivers iron during Fe-cofactor production. We performed a
spectroscopic characterization of the structure of iron bound to monomeric human frataxin,
mapped ferrochelatase’s intermolecular interface on frataxin and probed for probable
structures of the complex between frataxin and ferrochelatase with the goal of enhancing our
understanding of frataxin’s activities as an iron chaperone. We recently characterized the
structure of iron bound to monomeric yeast frataxin8 and proposed a docking interaction of
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frataxin with the yeast ferrochelatase,2 however the goal of this report was to confirm our
understanding of these iron binding and transfer events in the more physiologically relevant
human system. X-ray absorption spectroscopy (XAS) was utilized to examine the ligand
coordination structure and oxidation state of iron bound to monomeric human frataxin. Nuclear
magnetic resonance (NMR) spectroscopy was used to characterize frataxin residues at the
ferrochelatase-binding interface. Finally, docking simulations were performed to simulate how
frataxin binds and delivers iron to ferrochelatase. These results have provided a testable model
for iron delivery during cellular heme biosynthesis.
XAS studies performed on iron loaded monomeric human frataxin were used to confirm the
metal’s oxidation state and metal–ligand coordination structure. Reproducible independent
wild type frataxin XAS samples, covering residues 91–210, were prepared at 1 : 1 and 2 : 1 Fe
(II) to protein ratios ([protein] = 3.3 mM in 50 mM HEPES (pH = 7.0), 3.5 mM TCEP, 40%
glycerol).§ XANES edge energies for all samples are consistent with bulk iron existing in the
ferrous oxidation state (Supporting Fig. 1). Simulations of the iron 1s → 3d transitions for both
samples, showing dimensionless areas of 5.2 ± 0.5 and 4.8 ± 0.5 for 1 and 2 Fe bound, indicate
that bound iron is maintained in a symmetric 6-coordinate Fe(II) ligand environment.12 The 1s
→ 3d transition peak energies at 7122.5 and 7123.3 eV are consistent with high-spin Fe(II) in
both samples.12 Fourier transforms of the iron EXAFS (Fig. 1) indicate nearly symmetric
nearest-neighbor ligand scattering environments at R < 2.5 Å and minimal long-range ordered
scattering at R > 2.5 Å in both samples (Fig. 1). EXAFS fitting results confirm iron is
constrained in a 6-coordinate oxygen/nitrogen based nearest neighbor ligand environment with
average metal–ligand bond lengths centered at 2.12Å (Supporting Table 1). A minimal
improvement in our simulations were obtained upon inclusion of long-range (R > 2.8 Å ) carbon
scattering and there is no evidence for Fe⋯Fe scattering in iron loaded monomeric human
frataxin.
NMR spectroscopy was used to identify the ferrochelatase binding surface on iron-loaded
monomeric frataxin. Buffered iron was anaerobically added to 15N-labeled frataxin in a capped
NMR tube to achieve an oxygen free metal to protein stoichiometry of 1 : 1. Published binding
studies report frataxin interacts with ferrochelatase at a 1 : 2 protein monomer stoichiometry.
7 In order to be consistent with known binding stoichiometries, we anaerobically added 2
equivalents of ferrochelatase to the iron loaded 15N-labeled frataxin sample. All samples were
initially buffer exchanged into 10 mM HEPES (pH = 7), 50 mM NaCl, 0.1% deoxycholate to
prevent solution effects. 15N filtered TROSY-HSQC spectra were used to monitor frataxin’s
amide chemical shift perturbations, first upon iron binding and then upon complexation of
frataxin with ferrochelatase. Amide chemical shift perturbations coupled to complex formation
were observed on frataxin’s helical surface and strand-1 residues (Fig. 2). Similar results were
observed for the yeast orthologs.5 Frataxin’s surface exposed helix-1 conserved residues
(D104, E108 and E111) and conserved strand-1 residues (D122 and D124) showed appreciable
chemical shift perturbations in the frataxin:ferrochelatase complex. Additional conserved
helix-1 residues (D112, L113 and D115) were broadened during the iron titration beyond
detection (Supporting Fig. 2), as previously observed.4 Additional non-conserved helix-1
residues (F109 and A114), strand-1 residue S126 and helix-2 residues (K192, K195 and L197)
also showed amide perturbations following complex formation. These data, along with
published binding and molecular interface studies on the yeast and human orthologs, support
the idea that monomeric frataxin interacts with the ferrochelatase dimer predominantly utilizing
frataxin’s helical surface, including iron binding residues in the helix-1/strand-1 conserved
acidic residue patch of the protein.4,5,7,10
Docking simulations performed using ZDOCK13 place monomeric frataxin in an orientation
that promotes iron delivery to the ferrochelatase dimer (Fig. 3). Published structures of apo-
human frataxin and Co2+ loaded human ferrochelatase were used to structurally simulate
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docking.14,15 Rigorous selection criteria, determined from published structural and
biochemical details of frataxin and ferrochelatase’s initial iron binding residues, were
employed when identifying the best possible complex structure. The first selection criterion
took into account that human ferrochelatase is reported to initially bind iron using residues
H230, H231 and D383, located opposite to the membrane binding side of the molecule (Fig.
4).15 Iron is then directed down the substrate channel lined with Trp, Tyr and Arg residues
until it reaches the protein’s active site near the membrane surface (identified as the yellow
oval in Fig. 3). The second selection criterion utilized published data on the yeast ortholog5
and data in this report identified that frataxin binds ferrochelatase utilizing its helical surface
residues. Others and we have identified frataxin’s iron binding site on the protein’s helix-1,4,
5,8,16 a component region at frataxin’s intermolecular interface with ferrochelatase. Therefore,
a third selection criterion was that frataxin’s helix-1 iron binding site had to be close to
ferrochelatase’s initial metal binding or “acceptance” site. Finally, a monomeric protein
stoichiometry of 1 : 2 for frataxin to ferrochelatase has been reported,7,10 so the final selection
criterion for a possible structure included this condition. The lowest energy complex structure
from our simulations suggests iron-loaded monomeric frataxin docks on the exposed matrix
side of ferrochelatase in the region where the enzyme initially accepts iron. Frataxin’s iron
binding helix-1 residues D112 and D115 are within 9Å of ferrochelatase molecule 2’s initial
metal binding residues H230, H231 and D383 in the best simulated complex (Fig. 4). This
complex structure places iron, delivered by frataxin, in an orientation so that metal can first be
accepted by ferrochelatase. Ferrochelatase bound iron would then be free to be transferred
down the protein’s substrate channel, eventually reaching the enzyme’s active site (red arrow
and yellow oval, respectively in Fig. 3).
In conclusion, a combination of XAS and NMR studies was used to confirm that monomeric
frataxin binds high spin ferrous iron in a six-coordinate metal–ligand coordination environment
utilizing in part carboxylate oxygens as ligands from conserved acidic residues in frataxin’s
helix-1. Additional NMR studies confirm frataxin’s ferrochelatase docking surface is
constructed predominantly by helical surface residues on the protein’s helical face. Docking
simulations were used to generate a model of how iron-loaded monomeric frataxin docks to
the ferrochelatase dimer. Complex formation in this manner would allow for metal delivery
between the two protein partners, providing the ferrous iron required for in vivo heme
biosynthesis. Mutational and structural experiments, directed at testing our model for frataxin/
ferrochelatase binding, are currently in progress.
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Fig. 1.
EXAFS of frataxin bound iron. Raw EXAFS (black) and simulations (green) of 1 (A) and 2
(C) Fe bound. Fourier transforms of raw (black) and simulated (green) EXAFS of 1 (B) and 2
(D) Fe bound.
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Fig. 2.
Human frataxin residues perturbed at their amide position upon forming a complex with iron
and ferrochelatase. Unshifted (green) and shifted (red) residues identified on the apo-protein’s
structure. Yellow residues are line broadened beyond recognition resulting from Fe binding.
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Fig. 3.
Docking simulation of frataxin (Ftx) (green) with the ferrochelatase (Frch) dimer. Frataxin
interacts with ferrochelatase on the matrix exposed side of the protein dimer during iron
delivery (yellow ball). Delivered iron would then be available to be transported down
ferrochelatase’s substrate channel (red arrow) towards the enzyme’s active site (yellow oval)
located on the membrane side of the molecule.
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Fig. 4.
Expanded view of metal binding residues at the proposed frataxin (green)/ferrochelatase
molecule 2 (blue) interface.
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